Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Harker says Tilt wants to keep faith with shareholders

Harker says Tilt wants to keep faith with retail shareholders


By Jenny Ruth

May 29 (BusinessDesk) - Tilt Renewables decided to write to shareholders outlining the reasons why it isn’t paying a final dividend to pay “full respect” to its broad investor base, particularly its retail shareholders, says chair Bruce Harker.

Many of those smaller retail shareholders gained their shares first in Trustpower in 1995 when shares were distributed to Trustpower’s local Tauranga customers and then when Tilt was spun out of Trustpower in October 2016.

Tilt’s annual report has yet to be issued but Trustpower’s shows that at April 30 this year, it still had 11,678 shareholders owning fewer than 10,000 shares.

Infratil owns 65.3 percent of Tilt and Mercury New Zealand owns another 20 percent following last’s year’s takeover offer.

“There’s quite a large number of those shareholders who gained their shares in the 1995 share give-away still on the Tilt and Trustpower registers,” Harker says.

“We owe it to them to communicate with them as clearly as we can, even though they may not be following every notice of what the company’s up to,” he says.

Harkers says the letter wasn't in response to any shareholder complaints.

As the company has previously said, the board decided it was in the best interests of all shareholders not to pay a final dividend and to retain the cash within the business for anticipated project equity requirements

Tilt has a pipeline of wind and solar development projects across Australia and New Zealand. It commissioned the 54 megawatt Salt Creek wind farm in Victoria last year and in late 2020 raised A$260 million from shareholders for the 336 MW Dundonnell project it is aiming to commission in Victoria.



It is also near to committing to build a 133MW Waverley windfarm.

“Tilt Renewables also looks, to the extent possible, to fund these equity requirements with cash flows generated by the strong portfolio of operating assets and hence minimise the need to raise equity directly from shareholders,” Harker says in the letter.

He also outlined Tilt’s dividend policy, saying that the paying of dividends isn’t guaranteed and is at the board’s discretion.

That’s even though the company has actually paid regular dividends since its creation.

Tilt shares last traded at $2.35 and have risen 13 percent in the last 12 months.

(BusinessDesk)

ends

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Fish & Game Support: Canterbury Officer Of Health Warns On Nitrates In Water

"Nitrate testing of 114 drinking water samples from across the Canterbury plains showed that more than half of them were above the level considered safe in the world's largest ever study on the impacts of nitrates in drinking water." More>>

ALSO:

Partnerships Investment Round: Government Invests In Cancer Research, Pines, Ryegrass

The Government will invest $14.4 million into transformative new scientific research programmes including cutting-edge cancer treatment and vertical farming, Research, Science and Innovation Minister Megan Woods announced today. More>>

ALSO:

Stats: Net Migration Remains High

“Since late 2014, annual net migration has ranged between 48,000 and 64,000,” population indicators manager Tehseen Islam said. “The only previous time net migration was at these levels was for a short period in the early 2000s.” More>>

ALSO:

Retail: Costco To Open First NZ Store At Westgate In Auckland

American multi-national discount store operator Costco Wholesale is planning to open its first New Zealand store at the Westgate shopping centre in Auckland’s north-west. More>>

ALSO:

RNZ Report: Fungal Disease Claims Life Of Seventh Kākāpō

A seventh kākāpō being treated for the respiratory disease aspergillosis has died. Nora 1-A was just over 100 days old and was the sickest of the kākāpō being treated at the New Zealand Centre Conservation Medicine at Auckland Zoo. More>>